Sign Up to like & get
recommendations!
0
Published in 2020 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-020-00987-3
Abstract: Background and Objective INTP5 has been developed as a pegfilgrastim biosimilar. Single-dose, crossover study compared the pharmacokinetics and pharmacodynamics (PK/PD) of INTP5 (pegfilgrastim biosimilar) with reference pegfilgrastim (Neulasta ® , pegfilgrastim-ref) and a multiple-dose, parallel-group study compared the…
read more here.
Keywords:
immunogenicity;
intp5;
pegfilgrastim ref;
pegfilgrastim ... See more keywords